MedTrace Logo

Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis

NCT02764229 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2019-03-27

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to allow subjects completing study LYC-30937-2001 the opportunity to receive LYC-30937-EC 25 mg.

Conditions

  • Colitis, Ulcerative

Interventions

DRUG

LYC-30937-EC

LYC-30937-EC 25 mg by mouth once daily

Sponsors & Collaborators

  • Lycera Corp.

    lead INDUSTRY

Principal Investigators

  • H. Jeffrey Wilkins, MD · Lycera Corp.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-01
Primary Completion
2018-07-18
Completion
2018-07-18

Countries

  • United States
  • Czechia
  • Hungary
  • Netherlands
  • Poland
  • Serbia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02764229 on ClinicalTrials.gov